<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/233261-14-membered-lactone-ring-compounds-their-preparation-process-and-use-as-medicaments by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:36:41 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 233261:&quot;14 MEMBERED LACTONE RING COMPOUNDS, THEIR PREPARATION PROCESS AND USE AS MEDICAMENTS&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;14 MEMBERED LACTONE RING COMPOUNDS, THEIR PREPARATION PROCESS AND USE AS MEDICAMENTS&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The compounds of general formula (I): in which: either R1 and R2 , identical or different, represent a hydrogen atom, or a hydrocarbon radical containing up to 24 carbon atoms, saturated or unsaturated, optionally interrupted by one or more heteroatoms and optionally carrying one or more functional groups, or R1 and R2 form with the nitrogen atom to which they are linked a heterocycle optionally containing one or more heteroatoms chosen from nitrogen, oxygen and sulphur, or R1 and R2 together form a radical in which R&#x27;x and R&#x27;2, identical or different, represent a hydrogen atom or a hydrocarbon radical containing up to 23 carbon atoms, saturated or unsaturated, optionally interrupted by one or more heteroatons and optionally carrying one or more functional groups and Z represents a hydrogen atom or the remainder of a carboxylic acid containing up to 18 carbon atoms, the wavy line in position lO indicating that the methyl can be of R or S configuration or a mixture of R + S, as well as the addition salts with acids of the compounds of Formula (I).</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>The present invention relates to new erythromycin derivatives, their preparation process and their use as medicaments.<br>
A subject of the invention is the compounds of general formula (I): <br>
(Formula Removed)<br>
in which:<br>
either R1 and R2, identical or different, represent a<br>
hydrogen atom, or a hydrocarbon radical containing up to 24<br>
carbon atoms, saturated or unsaturated, optionally<br>
interrupted by one or more heteroatoms and optionally<br>
carrying one or more functional groups,<br>
or R1 and R2 form with the nitrogen atom to which they are<br>
linked a heterocycle optionally containing one or more<br>
heteroatoms chosen from nitrogen, oxygen and sulphur,<br>
or R1  and R2 together form a radical<br><br>
(Formula Removed)<br>
in which R'1  and R'2, identical or different, represent a hydrogen atom or a hydrocarbon radical containing up to 23 carbon atoms, saturated or unsaturated, optionally interrupted by one or more heteroatoms and optionally<br><br>
carrying one or more functional groups and Z represents a hydrogen atom or the remainder of a carboxylic acid containing up to 18 carbon atoms, the wavy line in position 10 indicating that the methyl can be of R or S configuration or a mixture of R + S as well as the addition salts with acids of the compounds of formula (I) .<br>
Among the addition salts with acids, there can be mentioned the salts formed with the following acids: acetic, propionic, trif luoroacetic, maleic, tartaric, methane-sulphonic, benzenesulphonic, p-toluenesulphonic and particularly stearic, ethylsuccinic or laurylsulphonic acid.<br>
The hydrocarbon radical which can be represented by R1 or R2 and R'1 or R'2 can be interrupted by one or more heteroatoms chosen from nitrogen, oxygen and sulphur and can carry one or more groups chosen from the group constituted by hydroxyl radicals, halogen atoms, N02 radicals, CHN radicals, the following radicals: alkyl, alkenyl or alkynyl, 0-alkyl, O-alkenyl or 0-alkynyl, S-alkyl, S-alkenyl or S-alkynyl and N-alkyl, N-alkenyl or N-alkynyl, containing up to 12 carbon atoms optionally substituted by one or more halogen atoms, the radical<br>
(Figure Removed), Ra and Rb, identical or different, representing<br>
a hydrogen atom or an alkyl radical containing up to 12 carbon atoms, the radical O<br>
II -C-R3 , R3 representing an alkyl radical containing up to 12<br>
carbon atoms, or an optionally substituted aryl or heteroaryl radical, carboxylic aryl, O-aryl or S-aryl radicals or heterocyclic aryl, O-aryl or S-aryl radicals with 5 or 6 members containing one or more heteroatoms, optionally substituted by one or more of the substituents mentioned above .<br>
The hydrocarbon radical which can be represented by R± or R2 and R1 or R'2 can be an alkyl, alkenyl, alkynyl, aralkyl, aralkenyl or aralkynyl radical.  In the definition<br>
of the substituents, the alkyl, alkenyl or alkynyl radical is preferably one of the following radicals: methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, terbutyl, decyl or dodecyl, vinyl, allyl, ethynyl, propynyl, propargyl, cyclobutyl, cyclopentyl or cyclohexyl.<br>
The aryl radical can be a phenyl or naphthyl radical.<br>
The aryl radical can also be a substituted or non-substituted heterocyclic radical such as the thienyl, furyl, pyrolyl, thiazolyl, oxazolyl, imidazolyl, thiadiazolyl, pyrazolyl or isopyrazolyl radical, a pyridyl, pyrimidyl, pyridazinyl or pyrazinyl radical, or also an indolyl, benzof urannyl , benzothiazyl or quinolinyl radical.  These aryl radicals can contain one or more of the above-mentioned groups .<br>
When R-L and R2 form with the nitrogen atom to which they are linked a heterocyclic radical, it is preferably one of the following radicals: pyrrolyl, pyrrolidinyl, pyridyl, pyrazinyl, pyrimidyl, piperidinyl, piperazinyl, quinuclidinyl, oxazolyl, isoxazolyl, morpholinyl, indolyl, imidazolyl, benzimidazolyl, triazolyl, thiazolyl, azetidinyl, aziridinyl.<br>
A more particular subject of the invention is the compounds of formula (I) in which Z represents a hydrogen atom, the compounds of formula (I) in which R1 represents a hydrogen atom, the compounds of formula (I) in which RI and R2 each represents a hydrogen atom.<br>
Among the preferred compounds of the invention, there can be mentioned the compounds of formula (I) in which R1 represents a hydrogen atom, there can be mentioned the compounds in which R1 and R2 together form a radical:<br>
in which Ar1 represents an optionally substituted aryl or heteroaryl radical and n represents an integer which can vary from 0 to 8 .<br>
Ar1 has as the preferred value, one or other of the<br>
preferred values indicated above for the aryl and heteroaryl radicals.  The optional substituent or substituents of A are those indicated above as functional groups.<br>
Among the preferred compounds of the invention, there can be mentioned the compounds of formula (I) in which RX and R2 form together a radical:<br>
(Figure Removed)in which p and q, identical or different, represent an integer varying from 0 to 6, A and B, identical or different, represent a hydrogen or halogen atom or an alkyl radical containing up to 8 carbon atoms, the geometry of the double bond being E or Z or an E + Z mixture, or A and B form a third bond with the carbon atoms to which they are linked and Ar2 represents an optionally substituted mono- or polycyclic aryl or heteroaryl radical.<br>
Among these compounds there can be mentioned quite particularly the compounds in which p and q represent the number 0, as well as those in which A and B represent a hydrogen atom.<br>
Among the preferred compounds of the invention, there can be mentioned the compounds of formula (I) in which R2 represents a radical:<br>
(Figure Removed)in which r represents an integer varying from 0 to 6 and Ar3 represents an optionally substituted aryl or heterocyclic radical, and more particularly those in which Ar3 represents a 4-quinolinyl radical optionally mono- or polysubstituted on one and/or the other of the 2 rings of the quinoline, for example those in which Ar3 represents a non-substituted 4-quinolinyl radical, 4-quinoleinyl substituted by a methoxy radical or a thiazolyl radical substituted by a pyridyl radical.<br>
A quite particular subject of the invention is the<br>
compounds of formula (I) in which r represents an integer varying from 1 to 4.<br>
Among the preferred compounds of the invention, there can be mentioned the compounds whose preparation is given hereafter in the experimental part and more particularly the compounds, the names of which follows:<br>
-	11,12-dideoxy 3-de ((2,6-dideoxy 3-C-methyl 3-O-methyl<br>
alpha-L-ribohexopyranosy1) oxy) 6-O-methyl 3-oxo 12,ll-(oxy-<br>
carbonyl (2-(3-(4-quinoleinyl) propyl) hydrazono)) erythromy-<br>
cine,<br>
-	11,12-dideoxy 3-de ((2,6-dideoxy 3-C-methyl 3-O-methyl<br>
alpha-L-ribohexopyranosy1) oxy) 6-O-methyl 3-oxo 12,ll-(oxy-<br>
carbonyl (2-(3-(7-methoxy-4-quinoleinyl) propyl) hydrazono))<br>
erythromycine,<br>
-	11,12-dideoxy 3-de ((2,6-dideoxy 3-C-methyl 3-O-methyl<br>
alpha-L-ribohexopyranosy1) oxy) 6-O-methyl 3-oxo 12,ll-(oxy-<br>
carbonyl (2-(3-(2-(3-pyridinyl-4-thiazolyl) propyl) hydra<br>
zono)) erythromycine.<br>
The products of general formula (I) possess a very good antibiotic activity on gram ® bacteria such as staphylococci, streptococci, pneumococci.<br>
The compounds of the invention can therefore be used as medicaments in the treatment of infections caused by sensitive germs and notably, in that of staphylococcia, such as staphylococcal septicemias, malignant staphylococcia of the face or skin, pyodermatitis, septic or suppurating sores, boils, anthrax, phlegmons, erysipelas and acne, staphylococcia such as primary or post-influenzal acute anginas, bronchopneumonia, pulmonary suppuration, streptococcal infection such as acute anginas, otitis, sinusitis, scarlet fever, pneumococcal infection such as pneumonia, bronchitis; brucellosis, diphtheria, gonococcal infection.<br>
The products of the present invention are also active against infections caused by germs such as Haemophilus influenzae, Rickettsia, Mycoplasma pneumoniae, Chlamydia, Legionella, Ureaplasma, Toxoplasma, or by germs of Mycobacterium type.<br>
Therefore a subject of the present invention is also, as medicaments and in particular antibiotic medicaments, the products of formula (I) as defined above, as well as their addition salts with pharmaceutically acceptable mineral or organic acids.<br>
A more particular subject of the invention is, as medicaments and in particular antibiotic medicaments, the products of Examples 5 or 11, 12 and 1 and their pharmaceutically acceptable salts.<br>
Also a subject of the invention is the<br>
pharmaceutical compositions containing as active ingredient at least one of the medicaments defined above.<br>
These compositions can be administered by buccal, rectal, parenteral route or by local route as a topical application on the skin and mucous membranes, but the preferred administration route is the buccal route.<br>
They can be solid or liquid and be presented in the pharmaceutical forms commonly used in human medicine, such as for example, plain or sugar-coated tablets, capsules, granules, suppositories, injectable preparations, ointments, creams, gels; they are prepared according to the usual methods.  The active ingredient or ingredients can be incorporated with excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous vehicles, fatty substances of animal or vegetable origin, paraffin derivatives, glycols, various wetting, dispersing or emulsifying agents, preservatives.<br>
These compositions can also be presented in the form of a powder intended to be dissolved extemporaneously in an appropriate vehicle, for example apyrogenic sterile water.<br>
The dose administered is variable according to the illness treated, the patient in question, the administration route and the product considered.  It can be, for example, comprised between 50 mg and 300 mg per day by oral route, for an adult, for the product of Example 5.<br>
Also a subject of the invention is a preparation process for compounds of formula (I), characterized in that a<br>
compound of formula (II):<br><br>
(Figure Removed)in which Z retains its previous meaning, is subjected either to the action of hydrazine NH2NH2 in order to obtain the compound of formula (IA):<br>
(Figure Removed)which is subjected if desired to the action of an R'2CHO or of a cetone R1-C-R'2 in which R1 and R'2 retain the same meaning as previously aldehyde in order to obtain the corresponding compound of formula (Ig):<br><br>
(Figure Removed)in which R'1 and R'2 retain the same meaning as previously, which is subjected if desired to the action of a reducing agent in order to obtain the corresponding compound of formula (Ic):<br>
(Figure Removed)in which R1 and R'2 retains its previous meaning, that is a compound of formula (I) in which R is a hydrogen and R2 represents a CHRR'2 radical, then if desired, the compound of formula (Ic) is subjected to the action of an agent capabl e of replacing the hydrogen atom of the NH group by an RI group as defined previously with the exception of the which hydrogen value, then if desired, the compound obtained is subjected to the action of an acid in order to form the salt and/or to the action of an esterification agent of the OH group in position 2'.<br>
The compounds of formula (II) used as starting products of the process of the invention are described and claimed in the European Patent Application EP 0596802.<br>
The preparation of the compounds of formula (II) is mentioned hereafter in the experimental part.<br>
In a preferred embodiment of the invention:<br>
-	the operation is carried out in the presence of an excess<br>
of hydrazine, at a temperature greater than ambient<br>
temperature for example a temperature comprised between 40<br>
and 80 °C, in a solvent such as acetonitrile, dioxane,<br>
dimethyIformamide, tetrahydrofuran, dimethoxy ethane or<br>
dimethylsulphoxide, (in the presence or in the absence of a<br>
base),<br>
-	the reaction with the aldehyde or the cetone takes place<br>
under the same temperature and solvent conditions,<br>
-	the reducing agent is NaBH3CN or hydrogen in the presence<br>
of a catalyst such as palladium, platinum and either in the<br>
presence or in the absence of an acid such as hydrochloric<br>
acid or acetic acid,<br>
-	esterification in position 2' is carried out according to<br>
standard processes,<br>
-	salification is carried out using acids according to<br>
standard processes.<br>
Also a subject of the invention is a variant of the preceding process, characterized in that the compound of formula (II):<br>
(Figure Removed)in which Z retains its previous meaning, is subjected to the action of a compound of formula NH2NHR2 in order to obtain the compound of formula (I'A):<br>
0 H which is subjected if desired, to the action of an agent<br>
capable of replacing the hydrogen atom of the NH group by an R- radical as defined previously with the exception of the hydrogen value or in order to obtain the corresponding compound of formula (I'B):<br>
(Figure Removed)which is subjected if desired, to the action of an esterification agent of the OH group in position 2' or to the action of an acid in order to form the salt, the preferred temperature and pressure conditions are those described above.<br>
The following examples illustrate the invention. EXAMPLE 1; 11,12-dideoxy 3-de-((2,6-dideoxy 3-C-methyl 3-O-methyl alpha L-ribohexopyranosy1) oxy) 6-O-methyl 3-oxo I2,ll-(oxycarbonyl (hydrozono) erythromycin isomer 10(R) and corresponding isomer 10(8)<br>
353 mg of 11-deoxy 10,11-didehydro 3-de(2,6-dideoxy<br>
3-C-methyl 3-O-methyl alpha-L-ribohexopyranosyl) oxy) 12-O-((IH-imidazol-i-yl) carbonyl) 6-O-methyl 3-oxo erythromycin 2'-acetate prepared as indicated in the European Patent Application EP 0596802 and 0.097 ml of hydrazine hydrate are suspended in 5ml of methyl cyanide and 0.5 ml of water.  The reaction mixture is heated to 60°C for 3 hours.  The reaction mixture is poured into water, extraction is carried out with ethyl acetate, the extracts are washed and dried.  The reaction mixture is chromato-graphed on silica, eluting with an isopropyl ether, triethylamine, methanol mixture (90/10/10).  101 mg of desired product (product A), Rf = 0.45, and 106 mg of corresponding product 10(S) (product B) are obtained. Product A:<br>
EXAMPLE 2; 11,12-dideoxy 3-de(2/6-dideoxy 3-C-methyl 3-O-methyl alpha-L-ribohexopyranosyl) oxy) 6-O-methyl 3-oxo 12,11 (oxycarbonyl (2-(3-phenyIpropylidene) hydrazono)) erythromycin<br>
285 mg of product A obtained in Example 1 and 156 mg of 3-phenylpropionaldehyde are put in solution in 2 ml of THF with a molecular sieve (4A°). 100 m of a molecular sieve<br>
(4A°) is added and the whole is heated at 60°C for 24 hours. Filtration is carried out, followed by concentration and purification by chromatography on silica, eluting with an ethyl acetate, triethylamine mixture (96-4).  The fractions of Rf = 0.41 are collected and 330 mg of desired product is obtained, Rf = 0.3.<br>
Analysis      % calculated      % found<br>
C	64.58	64.3<br>
H	8.26	8.3<br>
N	5.65	5.5<br>
NMR CDC13 ppm<br>
3.04	H1Q (q)<br>
4.46        H1;L (d, j = 3 HZ)<br>
5.05	H13 (dd)<br>
3.85	H2 (q)<br>
2.38	NMe (s)<br>
2.79	6 OMe (s)<br>
7.96	N=CH (t)<br>
2.85	CH2-*<br>
7.2,7.35   H aromatics<br>
2.61	NH=CH-CH2 (m) .<br>
EXAMPLE 3: 11,12-dideoxy 3-de((2,6-dideoxy 3-C-methyl 3-O-methyl alpha-L-ribohexopyranosyl) oxy) 6-O-methyl 3-oxo 12,11-(oxycarbonyl (2-(3-phenylpropyl) hydrazono)) erythromycin<br>
23 mg of sodium cyanoborohydride (NaBH3CN) is added to a solution containing 1.5 ml of methanol, 88 mg of the product of Example 2 and 50 ul of acetic acid.  After concentration, and taking up in ethyl acetate, water is added and the pH is adjusted to 8 using a solution of 2N soda. Decanting is carried out, followed by washing with a saturated solution of sodium chloride and drying.  The product obtained is chromatographed on silica, eluting with an isopopyl ether - methanol - triethylamine mixture (90-10-10).  The fractions of Rf = 0.33 are collected.  The mixture obtained is taken up in an ether-pentane mixture and filtered.  After evaporation, 70 mg of the expected product is obtained.<br>
Analysis    % calculated    % found<br><br>
13<br>
C	64.4	64.2<br>
H	8.51	8.3<br>
N	5.63	5.6<br>
NMR CDC13 ppm 3.74        H1Q (s) 5.03        H13 (dd) 3.86        H2 (q) 2.27        N(CH3)2 (s) 2.64        6 OMe (s) 2.72        CH2-* 7.13-7.28  H aromatics 5.35        H of NH (t).<br>
EXAMPLE 4: 11,12-dideoxy 3-de((2,6-dideoxy 3-C-methyl 3-O-methyl alpha-L-ribohexopyranosyl) oxy) 6-O-methyl 3-oxo 12,11 (oxycarbonyl (2-(3-(4-quinolinyl) 2(E)-propenylidene) hydrazono)) erythromycin<br>
125 mg of product A prepared in Example 1, 73 mg of 4-quinolinyl propenal whose preparation is given hereafter and 40 /il of acetic acid are agitated at ambient temperature for 5 hours.  The methanol is eliminated under reduced pressure and the resultant product is taken up in a methylene chloride- water mixture.  The pH is adjusted to 9 using a concentrated ammonium hydroxide solution.  The reaction medium is decanted, dried over magnesium sulphate, filtered and evaporated to dryness.  0.211 g of a product is obtained which is chromatographed on silica, eluting with a methylene chloride - methanol mixture (92-8).  The product of Rf = 0.4 is impasted in an ethyl acetate - pentane mixture (1-1). After separating, and rinsing with the minimum amount of ethyl acetate - pentane mixture, the product obtained is oven-dried under reduced pressure.  In this way 109 mg of the desired product is obtained. PREPARATION OF EXAMPLE 4; 4-quinoline propenal<br>
3.9 g of 4-quinoline carboxaldehyde is put in solution in 80 ml of methylene chloride.  The mixture is cooled down to 10°C ± 5°C and 8.3 g of 3-(triphenylphosphine) propenal (C6H5) 3P*=C-CHO is added over one hour 30 minutes while maintaining the temperature at 10°C.  The temperature is left<br><br>
to return to 20°C and agitation is continued for 24 hours. The reaction medium is cooled down again to 10°C and 0.4 g of (C6H5)3P=C-CHO is added.  Agitation is continued for 3 hours at ambient temperature.  The methylene chloride is evaporated off and a product is obtained which is chromatographed on silica eluting with an ethyl acetate - cyclohexane mixture (4-6).  2.12 g of desired product is isolated.  M.p. = approx. 9 0 ° C.<br>
EXAMPLE 5; 11,12-dideoxy 3-de((2,6-dideoxy 3-C-methyl 3-O-methyl alpha-L-ribohexopyranosyl) oxy) 6-o-methyl 3-oxo 12,11 (oxycarbonyl (2-(3-(4-quinolinyl) 2-propyl) hydrazono)) erythromycin<br>
0.38 g of the product prepared in Example 4 and 38 mg of platinum oxide are put in solution in 10 ml of ethyl acetate.  Hydrogenation is carried out under vigorous agitation for 24 hours.  After filtration, rinsing with ethyl acetate and evaporating under reduced pressure, 0.375 g of product is obtained which is taken up in 5 ml of methanol, 175 /il of acetic acid and 90 mg of sodium borohydride. Agitation is carried out for 3 hours at ambient temperature. The methanol is driven off and the residue is taken up in a methylene chloride - water mixture.  The pH is adjusted to 8-9 with a 28% ammonium hydroxide solution.  After decanting, washing with water, drying, filtering and evaporating to dryness, 0.37 g of product is obtained which is chromatographed on silica, eluting with an ethyl acetate -triethylamine mixture 96-4.  127 mg of a product is obtained (Rj = 0.25) which is separated, washed and dried.  90 mg of the desired product is obtained M.p. = 189°C. EXAMPLE 6; 11,12-dideoxy 3-de((2,6-dideoxy 3-C-methyl 3-O-methyl alpha-L-ribohexopyranosyl) oxy) 6-O-methyl 3-oxo 12,11-(oxycarbonyl (2-(3-(lH-benzimidazol-l-yl) propyl) hydrazono)) erythromycin<br>
A solution of 0.3 g of the product obtained in Example 1, 0.168 g of 3-imidazolyl-propanal (whose preparation is given hereafter) and 90 ml of acetic acid in 9 ml of methanol is agitated for 18 hours at ambient temperature, after this time 40 mg of sodium cyanoborohydride<br><br>
is added, agitation is continued for 5 hours then 120 mg of sodium cyanoborohydride and 200 jul of acetic acid are added. Agitation is continued for 48 hours, a methylene chloride and water mixture is added, the pH is adjusted to 8-9 with 32% ammonium hydroxide, the organic phase is separated off, dried and evaporated to dryness.  0.6 g of residue is obtained which is chromato-graphed on silica (eluant: ethyl acetate -methanol - TEA: 92-6-2), the product obtained is impasted in an ether - pentane mixture 1-5.  0.143 g of the crude desired product is collected which is dissolved in 1 ml of ethyl acetate, followed by filtration and crystallization by the addition of 3 ml of pentane, and after drying, 0.085 g of desired product is obtained (M.p. = 197°C).<br>
Analysis for c4iH63N5°10 785-98<br>
C      H      N<br>
% calculated   62.65    8.08    8.91 % found        62.5     8.1     8.8 NMR CDC13 ppm<br>
3.18: H1Q; 3.69 (s) : HI;L; 0.84 (t) : 15 CH3; 3.86 (q) : H2; 2.45: N-(CH3)2; 2.60 (s): 6 OCH3; 5.56 (t): NH;  2.65-2.81: NH-CH2~; 4.50: -CH2-N   ; 7.26 to 8.02: 5H benzimidazole.<br>
PREPARATION OF EXAMPLE 6: 3-imidazolyl propanal Stage A; 2-(2-(3-imidazolyl) ethyl) 1,3-dioxolane<br>
0.49 g of sodium hydride dispersed in oil at 50% is added to a solution of 1.2 g of benzimidazole in 15 ml of dimethylformamide.  The temperature rises to 35°C, ten minutes after the end of the gaseous release, 1.2 ml of 2-(2-bromoethyl) 1,3-dioxolane is added while allowing the temperature to rise to 35°C.  Agitation is carried out for two hours, water saturated with sodium chloride is added, extraction is carried out with ether, the extracts are dried, filtered and evaporated under reduced pressure, 2 g of residue is obtained which is chromatographed on silica eluting with methylene chloride - methanol (95-5).  In this way 1.6 g of desired product is collected. NMR CDC13: 2.25 and 4.35: CH2's of the ethyl; 3.85 to 4.00: CH2/s of the<br>
dioxolane; 4.87: CH dioxolane; 7.29-7.45-7.81: 4H benzimidazole; 7.92: H in position 2 of the imidazole. STAGE B: 3-imidazolyl propanal<br>
A solution of 1.6 g of the product obtained in Stage A, 1.45 g of paratoluene sulphonic acid in 60 ml of methanol is agitated for 5 hours under reflux.  The pH is adjusted to 8 with potassium carbonate, the methanol is eliminated under reduced pressure, extraction is carried out with methylene chloride, followed by washing with water, drying and evaporating to dryness under reduced pressure, 1.45 g of intermediate dimethoxy cetal is obtained which is agitated at 40°C for 18 hours, in the presence of 70 ml of acetone and 34 ml of 2N hydrochloric acid, the acetone is evaporated off under reduced pressure and the pH is adjusted to 8-9 by the addition of 32% ammonium hydroxide, extraction is carried out with methylene chloride, the extracts are washed with water, dried and evaporated to dryness under reduced pressure, 1.13 g of product is collected which is chromatographed on silica, eluant: methylene chloride - methanol 95-5.  0.796 g of desired product is obtained. NMR CDC13 250 MHz<br>
3.07 (t)-4.52 (t): CH2's of the ethyl; 7.25 to 7.50: thearomatics; 9.79 (s): CH of the aldehyde. EXAMPLE 7; 11,12-dideoxy 3-de((2,6-dideoxy 3-C-methyl 3-O-methyl alpha-L-ribohexopyranosyl) oxy) 6-o-methyl 3-oxo 12,11-(oxycarbonyl (2-(3-(2-phenyl 5-thiazolyl) propyl) hydrazono)) erythromycin<br>
60 mg of sodium cyanoborohydride are added to a mixture 200 mg of the product obtained in Example 1, 139 mg of 3-(2-phenyl 5-thiazolyl) propanal (whose preparation is given hereafter), 180 ml of acetic acid and 7 ml of methanol are agitated for 4 hours at ambient temperature and their agitation takes place for 18 hours at ambiant temperature. Evaporation to dryness under reduced pressure is carried out, the residue is taken up in a water - ethyl acetate mixture and the pH is adjusted to 9 with an aqueous ammonium hydroxide solution.  Extraction is carried out with ethyl acetate, the extracts are washed with water, dried,<br>
evaporated to dryness under reduced pressure.  354 mg of product is collected which is chromatographed on silica, eluant: ethyl acetate then ethyl acetate - triethylamine (96/4).  170 mg of product is collected which is crystallized from an ethyl acetate - pentane mixture 1/5.  In this way 80 mg of the desired product is obtained. Analysis for C43H64N4O10S  829.07<br>
C    H     N     S<br>
% calculated   62.3   7.78   6.76   3.87 % found        62.0   7.8    6.8    4.0 NMR CDC13 300 MHz<br>
3.17 (m): H10; 1.07 (d): 14 CH3; 1.48: 15 CH3; 3.87 (q): H2; 2.26 (s): N-(CH3)2; 3.53 (m): 2'OH; 2.67 (s): 6-OCH3; 5.43 (t): NH; 2.86 (m)-1.95 (m)-3.03 (m):  the propyl CH2's; 7.55 (s): H of the thiazole; 7.39 (m) 3H and 7.89 (m) 2H: aromatics; 1.19 (d): Hg.<br>
PREPARATION OF EXAMPLE 7: 2-phenyl 5-thiazole propanal Stage A; 2-phenyl 5-carbethoxy thiazole<br>
A solution of ethyl formyl beta chloracetate in 240 ml of benzene is added to a suspension of 78 g of thiobenzamide in 200 ml of benzene.  Heating under reflux is carried out for 3 hours 30 minutes while eliminating the water formed.  The reaction medium is cooled down and 320 ml of a 20% solution of potassium carbonate and 220 cm3 of water are added slowly, extraction is carried out with ether, followed by washing, drying and distillation under reduced pressure,  75.5 g of desired product is obtained. Stage B: 2-phenyl 5-thiazole carboxylic acid<br>
28.56 g of potash in pellets in solution in 410 ml of ethanol is added to a solution of 75.5 g of the product obtained in Stage A, in 130 ml of ethanol, the whole mixture is heated for 15 minutes under reflux, cooled down and the potassium salt is separated off, washed with ether and dried under reduced pressure.  53.5 g of intermediate potassium salt is obtained which is dissolved in 1.2 litres of water and acidified to pH 1 with a concentrated hydrochloric acid solution after filtration, 29 g of desired product is collected (M.p. = 192°C).  24.5 g of product is<br>
recrystallized from 750 ml of toluene.  20 g of desired product is obtained.  M.p. = 195°C. Analysis for C10H7N02S  205.2<br>
% calculated 58.52 3.43 6.82 15.6 % found 58.5 3.7 6.8 15.2 Stage C: methyl 2-phenyl 5-thiazole carboxylate<br>
2.5 ml of acetyl chloride is added to a solution of 4.77 g of the acid obtained in Stage B in 160 ml of methanol, and the mixture is heated under reflux for 18 hours.  After bringing to dryness under reduced pressure, taking up in ethyl acetate, filtration and concentration to a reduced volume, the crystals obtained are separated off.  The mother liquors are washed with soda, extraction is carried out with ethyl acetate, followed by washing with water and evaporating to dryness, the 2 crystallized fractions are united to obtain 4.54 g of desired product (M.p. = 108°C). Stage D; 2-phenyl 5-formyl thiazol Reduction:<br>
A solution of 4.5 g of the product obtained in Stage C in 35 ml of tetrahydrofuran is added over 20 minutes and while maintaining the temperature at 10°C to a suspension of 1.45 g of lithium-aluminium hydride in 65 ml of tetrahydrofuran cooled down to 10°C, the mixture is agitated for 45 minutes at 10°C, then for 2 hours at ambient temperature.  10 then 50% tetrahydrofuran in water is added while maintaining the temperature below 20°C, 15 ml of a solution of potassium and sodium tartrate is added, filtration is carried out followed by rinsing and bringing to dryness under reduced pressure;  the residue obtained is impasted in hexane, separated and dried at 40°C, under reduced pressure, and 3.6 g of product is collected.  M.p. = 82°C. Oxidation:<br>
3.57 g of the product obtained above is agitated for 2 hours 30 minutes at ambient temperature with 143 ml of toluene and 17.9 g of manganese dioxide.  After filtration and bringing to dryness under reduced pressure, the residue is taken up in hexane, separated and dried at 40°C under<br>
reduced pressure, and 3.09 g of desired product is collected.<br>
M.p. = 94°C.<br>
Stage E: 3-(2-phenyl 5-thiazolyl) propenal<br>
5 g of (formylmethylene) triphenylphosphorane is added over 10 minutes to a solution of 2.098 g of the product obtained in Stage D, and agitation is carried out for 27 hours at ambient temperature.  After evaporating to dryness under reduced pressure, 6.60 g of product is collected which is chromatographed on silica eluting with ethyl acetate -cyclohexane (2-8).  1.22 g of product is obtained which is impasted in pentane in order to obtain 1.047 g of the desired product (M.p. = 104°C). NMR CDC13 (250 MHz)<br>
8.04 (s): H triazole; 6.49 (ddJ = 7.5) and 7.69 (dJ = 15.5) the propene H's; 9.67 (J = 7.5) CHO; 7.50 (m) 3H and 7.97 (m) 2 H: the aromatics. Stage F; 3-(2-phenyl 5-thiazolyl) propenol<br>
900 mg of the aldehyde obtained in Stage E above is added in portions to a suspension of 475 mg of sodium borohydride in 50 ml of ethanol, then the mixture is agitated for 20 minutes at ambient temperature then the excess sodium borohydride is destroyed by adding acetone.  Evaporation to dryness under reduced pressure is carried out followed by taking up in ethyl acetate, washing with salt water, drying and bringing to dryness under reduced pressure, and 960 mg of product is obtained, used as it is for the following stage. Stage G; 2-phenyl 5-thiazole propanol<br>
A solution of 960 mg of the product obtained in Stage F in 10 ml of methanol is hydrogenated for 12 hours under 1 atmosphere then for 9 hours under 1.4 atmospheres in the presence of 150 mg of palladium on charcoal.  After filtration, evaporation to dryness under reduced pressure is carried out and the residue is chromatographed on silica (eluant: ethyl acetate - cyclohexane (4-6)).  759 mg of desired product is collected. NMR CDC13 200 MHz<br>
1.52 (m): OH; 3.74 (m) - 1.97 (m) - 2.92 (dt): the CH2's; 20<br>
Stage H: 2-phenyl 5-thiazole propanal<br>
1.27 g of pyridinium sulphotrioxide complex is added to a solution cooled down to 10°C of 584 mg of the product obtained in the previous stage, 800 ul of dimethyIsulphoxide, 1.15 ml of triethylamine and 8 ml of methylene chloride while maintaining the temperature at 10°C, the whole is agitated for one hour 15 minutes at 10°C, then left to return to ambient temperature, extraction is carried out with methylene chloride, followed by washing with water, drying and evaporating to dryness under reduced pressure, 806 mg of product is collected which is chromatographed on silica (eluant: ethyl acetate - cyclohexane (3-7)), and 450 mg of the desired product is obtained. NMR CDC13 200 MHz<br>
2.88-3.20 (t): the propyl CH2's; 7.55 (s): H thiazole; 7.40 (m): 3H and 7.87 (m) 2H: the aromatic H's; 9.85 (ws): CHO. EXAMPLE 8; 11,12-dideoxy 3-de((2,6-dideoxy 3-c-methyl 3-O-methyl alpha-L-ribohexopyranosy1) oxy) 6-O-methyl 3-oxo 12,11-(oxycarbonyl (2-(3-(4-phenyl IH-imidazol 1-yl) propyl) hydrazono)) erythromycin<br>
125 mg of the product obtained in Example 1, 80 mg of 3-(4-phenyl IH-imidazole 1-yl) propanal (whose preparation is given hereafter) and 2 ml of methanol are agitated for 20 hours.  54 mg of sodium cyanoborohydride is added. Concentration under reduced pressure is carried out, the residue is taken up in 20 ml of ethyl acetate, washed with soda then with water saturated with sodium chloride, dried and evaporated to dryness under reduced pressure, and the residue is chromatographed on silica (eluant: chloroform -methanol - ammonium hydroxide 95/5/0.5), the crude product is taken up in an ether - ethyl acetate mixture, filtered, evaporated to dryness and 85 mg of the desired product is collected. Analysis for C43H65N5O10   812.02<br>
C     H      N<br>
% calculated   63.6   8.07   8.62 % found        63.4   8.2    8.3 NMR CDC13 400 MHz<br>
3.70 (s): H in position 11; 4.98 (dd): H13; 3.86 (q): H in<br>
position 2; 2.26 (s): N-(CH3)2; 2.63: 6-OCH3; 5.54 (t): NH;<br>
4.27 and 1.97: the propyl CH2's; 7.3 (d) - 7.57 (d): 2H<br>
imidazole; 7.2 - 7.35 - 7.8: the aroraatics.<br>
PREPARATION OF EXAMPLE 8; 3-(4-phenyl lH-imidazol 1-yl)<br>
propanal<br>
Stage A : 3-(4-phenyl IH-imidazol 1-yl) ethyl 1,3-dioxolane<br>
The operation is carried out as in Stage A of the preparation of Example 6, starting with 1.44 g of 4-phenylimidazole and 1.17 ml of bromoethyldioxolane, and after chromatography on silica (eluant: ACOEt) 1.8 g of expected product is obtained. NMR CDC13<br>
2.19 (d,t) and 4.13 (t): propyl CH2; 3.8-4.05: the CH2's of dioxolane; 4,88 (t) : H oxolane; 7.23 and 7.53: the imidazole CH's; 7.23 - 7.37 - 7.75: the aromatics. Stage B; 3-(4-phenyl IH-imidazol 1-yl) propanal<br>
1.77 g of the product obtained in Stage A above, 35 ml of acetone and 30 ml of 2N hydrochloric acid are heated for 20 hours at 60°C.  The acetone is then eliminated under reduced pressure and the solution is neutralized by adding sodium bicarbonate in sticks, then extraction is carried out with ethyl acetate, followed by drying and evaporating to dryness under reduced pressure.  The residue is chromatographed on silica (eluant: ethyl acetate - methanol (97-3)).  900 mg of desired product is collected. NMR CDC13 250 MHz<br>
9.81 (s): CHO; 7.10 to 7.76: the imidazole and aromatic H's; 3.01 (t) and 4.29 (t): the propyl H's.<br>
EXAMPLE 9; 11,12-dideoxy 3-de((2,6-dideoxy 3-C-methyl 3-O-methyl alpha-L-ribohexopyranosy1) oxy) 6-O-methyl 12,11-(oxycarbonyl (2-(3-(3-phenyl 1,2,4-oxodiazol 5-yl) propyl) hydrazono) erythromycin<br>
The operation is carried out as in Example 6<br>
starting with 125 mg of the product obtained as in Example 1, using 40 mg of 3~(3-phenyl 1,2,4-oxadiazol 5-yl) propanal (whose preparation is described hereafter).  After chromatography on silica, eluant: isopropyl ether -<br>
triethylamine - methanol (90-10-10) and crystallization from<br>
isopropyl ether - methanol, 107 mg of expected product is<br>
obtained.<br>
Analysis for C42H63N501;L  814.00<br>
C     H    N<br>
% calculated 61.97 7.8 8.6 % found 61.7 7.9 8.5 NMR CDC13 300 MHz<br>
3.74 (s): Hl:L; 5.03 (dd) : H13; 3.87 (q) : H2; 2.27 (s) : 6-OCH3; 2.27 (s): N-(CH3)2; 5.49 (t): NH; 3.17 (m) and 2.11 (m): the propyl CH2's; 7.47 to 8.08: the aromatics. PREPARATION OF EXAMPLE 9; 3-(3-phenyl 1,2,4-oxadiazol 5-yl) propanal Stage A: 3-(3-phenyl 1,2,4-oxadiazol 5-yl) propanol<br>
A solution of 2.5 ml of borane-methyl sulphide complex, in 2M solution in tetrahydrofuran, 920 mg of 3-(3-phenyl 1,2,4-oxadiazol 5-yl) propanoic acid (prepared according to R.M. SRIRASTAVA et al. J. Heterocycl. Chem. , 2_1, 1193 (1984) and 20 ml of tetrahydrofuran is agitated for one hour at ambient temperature.  10 ml of methanol is added over 5 minutes.  Evaporation to dryness under reduced pressure is carried out and the residue is chromatographed on silica (eluant: ethyl acetate - hexane (6-4)).  485 mg of expected product is collected. NMR CDC1,, 250 MHz<br>
•J<br>
2.07 (ws): OH; 2.14 (m) - 3.10 (t) - 3.8 (t): the CH2/s; 7.41<br>
- 7.54 - 8.06: the aromatics.Stage B; 3-(3-phenyl 1,2,4-oxadiazol 5-yl) propanal<br>
1.07 g of pyridinium sulphotrioxide complex is added to a solution cooled down to 10°C of 460 mg of the product obtained in Stage A, 680 ul of dimethyl sulphoxide and 970 ul of triethylamine in 5 ml of methylene chloride while maintaining the temperature at 10°C, the reaction medium is left to return to ambient temperature, 15 ml of methylene chloride is added, followed by washing with water, drying, evaporating to dryness under reduced pressure and chromato-graphing on silica (eluant: ethyl acetate - hexane 4-6) and 365 mg of the desired product is obtained.<br>
NMR CDC13<br>
3.13 (m) - 3.26 (m) : the CH2/s; 7.49 to 8.05: the aromatics.<br>
EXAMPLE 10! 11,12-dideoxy 3-de((2,6-dideoxy 3-C-methyl 3-O-<br>
methyl alpha-L-ribohexopyranosy1) oxy) 6-o-methyl 3-oxo<br>
12,ll-(oxycarbonyl (2-(3-(2-chlorophenyl) propyl) hydrazono)<br>
erythromycin<br>
The operation is carried out as in Example 6 starting with 125 rag of the product obtained in Example 1, using 67 mg of 2-chlorophenyl propanal (whose preparation is given hereafter).  After chromatography on silica (eluant: isopropyl ether -triethylamine - methanol (90-10-10)), 48 mg of desired product is collected. Analysis for C40H62C1N3010   780.40<br>
C      H      N      Cl<br>
% calculated   61.56   8.01   5.38   4.45 % found        61.4    8.0    5.4    4.5 NMR CDC1., 400 MHz<br>
-)<br>
3.73 (s) : H in position 11; 5.13 (dd): H in position 13; 3.87 (q): H in position 2; 2.26 (s): N-(CH3)2; 2.64 (s): 6-OCH3; 5.36 (t): NH; 1.83 (m) - 2.70 (m) - 2.79 (m): the CH2's; 7.05 to 7.2: the aromatics.<br>
PREPARATION OF EXAMPLE 10! 3-(2-chlorophenyl) propanal Stage A: methyl 3-(2-chlorophenyl) propanoate<br>
4.35 g of metachlorocinamic acid, 430 mg of palladium on activated charcoal and 70 ml of methanol are agitated for one hour under an inert atmosphere.  Agitation is then carried out for 3 hours under a hydrogen atmosphere.  The reaction medium is filtered and evaporated to dryness under reduced pressure and the residue is chromatographed on silica (eluant: ethyl acetate - hexane (2-8)), 3.1 g of desired product is obtained.<br>
NMR CDC13 250 MHz<br>
2.6 (t) - 2.8 (t): the CH2's; 3.6 (s): OCH3; 7.05 - 7.37: the aromatics. Stage B; 3-(2-chlorophenyl) propanol<br>
30 ml of diisobutylaluminium hydride in a 1M solution in tetrahydrofuran is added at 0°C to a solution of 1.85 g of the product obtained in Stage A, in 20 ml of tetrahydrofuran.<br>
The mixture is left to return to ambient temperature and agitated for 2 hours.  A solution of mixed sodium-potassium tartrate is added, dilution is carried out with tetrahydro-furan, followed by filtration and evaporation to dryness under reduced pressure.  The residue is chromatographed on silica (eluant: ethyl acetate - hexane (2-8)) and 1 g of desired product is obtained. Stage C; 3-(2-chlorophenyl) propanal<br>
The operation is carried out as in Stage B of Preparation 9, starting with 1 g of the product obtained in Stage B above, using 2.5 ml of triethylamine, 1.75 ml of dimethyl sulphoxide and 2.8 g of pyridinium sulphotrioxide complex.  After chromatography on silica, eluant: ethyl acetate - hexane (1-9), 425 mg (43%) of desired product is obtained. NMR CDC13 250 MHz<br>
2.79 (m) and 2.94 (m): the CH2's; 7.05 to 7.25: the aromatics; 9.82 (t): CHO.<br>
EXAMPLE 11 : 11,12-dideoxy 3-de ((2,6-dideoxy 3-C-methyl 3-0-methyl alpha-ribohexopyranosy1) oxy) 6-O-methyl 3-oxo 12,11-(oxycarbonyl (2-(3-(4-quinolinyl) 2-propyl) hydrazono)) erythromycin<br>
Stage A: 11,12-dideoxy 3-de ((2,6-dideoxy 3-C-methyl 3-O-methyl alpha L-ribohexopyranosy1) oxy) 6-O-methyl 3-oxo 12,ll-(oxycarbonyl (hydrazono) erythromycin isomer 10(R) and corresponding isomer 10(S).<br>
17.65 g of 11-deoxy 10,11-didehydro 3-de(2,6-dideoxy 3-C-methyl 3-0-methyl aIpha-L-ribohexopyranosy1) oxy) 12-O-((IH-imidazol-l-yl) carbonyl) 6-O-methyl 3-oxo erythromycin 2'-acetate is put in solution in 176 ml of methyl cyanide. 4.07 g of caesium carbonate and 25.5 ml of hydrazine hydrate are added.  After heating for 10 minutes at 85°C, the solvent is driven off under reduced pressure at 40°C, extraction is carried out with methylene chloride, followed by washing with water and drying, the solvent is evaporated off, the residue is taken up in methanol, the precipitate is separated out, dried at 50°C under reduced pressure and 6.04 g of product is collected.  The mother liquors are concentrated to dryness,<br>
the residue is chromatographed on silica (eluant: isopropyl ether - methanol - triethylamine 80-10-10) and 0.83 g of isomer A (Rf = 0.4) and 2.65 g of isomer B (Rf = 0.2) are collected.<br>
Stage B: 11,12-dideoxy 3-de((2,6-dideoxy 3-C-methyl 3-O-methyl alpha-L-ribohexopyranosyl) oxy) 6-O-methyl 3-oxo 12,ll(oxycarbonyl (2-(3-(4-quinolinyl) 2-propyl) hydrazono)) erythromycin.<br>
13 g of the product obtained as in Stage A and 4.66 g of 4-quinoline propanal prepared as indicated below are suspended in 130 ml of methanol.  4.8 ml of acetic acid is added and agitation is carried out for 20 hours at ambient temperature.  Next 5.3 g of sodium cyanoborohydride is added then agitation is continued for 4 hours.  The methanol is eliminated under reduced pressure, extraction is carried out with ethyl acetate, followed by washing with an aqueous solution of N soda then with water; the solvent is evaporated from the organic phase, the residue is chromatographed on silica (eluant: ethyl acetate - triethylamine 97-3) and 12.7 g of product is obtained, Rf = 0.15.  After another chromatography on silica (eluant: methylene chloride -methanol 95-5 then 85-15) and crystallization from isopropyl ether, the pure product is obtained, M.p. = 183°C, the analyses of which are identical to those of Example 5. PREPARATION OF EXAMPLE 11; 4-quinoline propanal. Stage A: 2-(4-quinolinyl ethenyl) 1,3-dioxolane.<br>
3.15 g of 4-quinoline carboxaldehyde and 8.6 g of [1,3-(dioxalan-2-yl) methyl] triphenylphosphonium bromide are suspended in 40 ml of tetrahydrofuran, the suspension is cooled down to -30°C then 2.5 g of potassium terbutylate is added and agitation is carried out for one hour.  The reaction medium is allowed to return to ambient temperature, agitated for 3 hours, poured into a water/ice mixture, extraction is carried out with methylene chloride, followed by washing with water and drying, the solvent is evaporated off under reduced pressure, the residue is taken up in an ethyl ether - pentane mixture 3-7, agitation is carried out for 2 hours, followed by filtration, and the solvent is<br>
evaporated from the filtrate and 3.99 g of expected product<br>
is obtained.<br>
Stage B; 2-[2-(4-quinolinyl) ethyl] 1,3-dioxolane.<br>
4.3 g of the product obtained in Stage A is dissolved in 40 ml of methanol, 0.215 g of activated charcoal with 10% palladium is added and hydrogenation is carried out for 2 hours under a pressure of 1500 mbars.  After filtration, rinsing with methanol, the solvent is evaporated off and 4.2 g of expected product is collected which is used as it is for the following stage. Stage C; 4-quinoline propanal.<br>
4.2 g of the product obtained in Stage B is dissolved in 70 ml of acetone and 70ml of 2N hydrochloric acid is added. Heating is carried out for 6 hours at 40°C, the acetone is eliminated under reduced pressure, extraction is carried out with ethyl acetate, followed by washing with water, the aqueous phase is adjusted to pH = 9 with an aqueous solution of ammonium hydroxide.  Extraction is carried out with ethyl acetate, the organic phases are united, dried and the solvent is evaporated off.  After chromatography on silica (eluant: ethyl acetate - cyclohexane 6-4) 1.36 g of expected product is obtained.<br>
EXAMPLE 12; 11,12-dideoxy 3-de((2,6-dideoxy 3-C-methyl 3-O-methyl alpha-L-ribohexopyranosyl)oxy) 6-o-methyl 3-oxo 12,11-(oxycarbonyl 2-(3-(7-methoxy-4-quinolinyl) propyl) hydrazono)) erythromycin.<br>
299 mg of 7-methoxy 4-quinoline propanal prepared as indicated below and 313.9 mg of product A prepared in Example 1 and 120 /ul of acetic acid are dissolved in 2 ml of methanol.  Agitation is carried out for 2 hours 15 minutes at ambient temperature then 62.84 g of sodium cyanoborohydride is added.  Agitation is continued for 20 hours at ambient temperature.  The reaction medium is poured into 50 ml of ethyl acetate, washed with 15 ml of N soda then with water, dried, the solvent is evaporated off under reduced pressure and 549 mg of product is collected which is purified by chromatography on silica (eluant: isopropyl ether-methanol-triethylamine 80-10-10) then (chloroform-methanol-ammonium<br>
hydroxide 96-4-0,4).  37.2 mg of expected product is<br>
collected, Rf = 0.2.<br>
Analysis<br>
C     H     N<br>
% calculated   63.84   8.04   6.77 % found        63.8    8.1    6.6 NMR CDC13 300 MHz<br>
3.74 (s) : H1;L; 3.17 (m) : NH-£H2; 3.95 (s) : OCH3 of the quinoline; 7.16-7.41 (d)-8.00 (d)-8.70 (d): H quinoline; 3.87 (q): H2; 2.65 (s): 6-OCH3; 2.65 (m): HQ; 0.82 (t): CH3-CH2. PREPARATION OF EXAMPLE 12t 7-methoxy 4-quinoline propanal. Stage A; 2-[(7-methoxy 4-quinolinyl) ethenyl] 1,3-dioxolane.<br>
The operation is carried out as in the preparation of Example 11, Stage A starting with 787 mg of 7-methoxy 4-quinoline carboxaldehyde.  2.61 g of product is obtained which is chromatographed on silica (eluant: chloroform -ethyl acetate 7-3).  931 mg of expected product is obtained. Stage B; 2-[2-(7-methoxy 4-quinoline) ethyl] 1,3-dioxolane.<br>
The operation is carried out as in the preparation of Example 11 Stage B using 931 mg of the product prepared in Stage A and 869 mg of expected product is obtained. Stage C: 2-(7-methoxy 4-quinoline) propanal.<br>
The operation is carried out as in the preparation of Example 11 Stage C using 845 mg of the product obtained in Stage B.  310 mg of expected product is obtained, Rf = 0.15. EXAMPLE 13; 11,12-dideoxy 3-de ((2,6-dideoxy 3-C-methyl 3-O-methyl alpha-L-ribohexopyranosyl)oxy) 6-O-methyl 3-oxo 12,11-(oxycarbonyl 2-(3-(2-(3-pyridinyl-4-thiazolyl) propyl) hydrazono)) erythromycin.<br>
The operation is carried out as in Example 12, starting with 158 mg of 2-(3-pyridinyl) 4-thiazole propanal, 370 mg of product A prepared in Example 1 and 70 p.1 of acetic acid in 3.7 ml of methanol then after agitation for 4 hours at ambient temperature, 75 mg of sodium cyanoborohydride is added.  After agitation for 16 hours at ambient temperature, another 16 mg of aldehyde and 20 mg of reducing agent are added and agitation is continued for 3 hours.  Water and ethyl acetate are added, followed by alkalinizing to pH = 9<br><br>
using ammonium hydroxide, the organic phase is washed with<br>
water, dried and the solvent is evaporated off under reduced<br>
pressure.  After chromatography on silica (eluant: isopropyl<br>
ether - methanol - triethylamine 80-10-10), 203 mg of<br>
expected product is obtained.<br>
3.18 (m) : H10; 3.74 (s) : HII;- 7.05 (s) : H5 thiazole; 7.37<br>
(dd)-8.24 (ddd)-8.62 (dd)-9.13 (dd): pyridine; 3.86 (q): H2;<br>
2.65 (s): 6-OCH3; 2.66 (m); H8; 0.85 (t): CH3-CH2.<br>
PREPARATION OF EXAMPLE 13; 2-(3-pyridinyl) 4-thiazole<br>
propanal.<br>
Stage A: [[2-(3-pyridinyl) 4-thiazolyl] ethenyl] 1,3-<br>
dioxolane.<br>
The operation is carried out as in the preparation of Example 11 Stage A starting with 2.6 g of 2-(3-pyridinyl) 4-thiazolyl carboxaldehyde.  After chromatography on silica (eluant: ethyl acetate - hexane 2-1) 4.8 g of expected product is obtained (Rf =0.35 used as it is for the following stage.<br>
Stage B: 2-[2-((3-pyridinyl) 4-thiazolyl) ethyl] 1,3-dioxolane.<br>
The operation is carried out as in the preparation of Example 11 Stage B starting with 4.8 g of the product prepared in Stage A and after chromatographing the residue on silica (eluant: ethyl acetate - cyclohexane 2-1) 1.4 g of expected product is obtained. Stage C: 2-(3-pyridinyl) 4-thiazolyl propanal.<br>
The operation is carried out as in the preparation of Example 11 Stage C starting with 1.2 g of the product prepared in Stage B.  After chromatography on silica (eluant: ethyl acetate - hexane 2-1) 468 mg of expected product is obtained.<br>
By operating as in the previous examples starting with the compound of Example 1 and the appropriate aldehyde, the following products were prepared:<br>
EXAMPLE 14; 11,12-dideoxy 3-de ((2,6-dideoxy 3-C-methyl 3-O-methyl alpha-L-ribohexopyranosyl) oxy) 6-O-methyl 3-oxo 12,11-(oxycarbonyl 2-(3-(lH-imidazol-l-yl) propyl) hydrazono)) erythromycin.<br><br>
NMR (CDC13) 300 MHz:<br>
0.83 (t): CH3-CH2; 1.08 (d)-1.17 (d)-1.25 (d)-1.3 (d)-1.35<br>
(d) : the CH_3-CH's; 1.3 (s)-1.47 (s) : 6 and 12 Me; 2.12 (m) :<br>
CH2-CH.2-CH2; 2.27 (s) : N(Me)2; 2.45 (m) : H'3; 2.59 (s) : 6-<br>
OMe; 3.05 (m): H4; 2.6 to 3.2: H'2, HIQ: HQ and CH2NH; 3.53<br>
(m) : H'5; 3.72 (s) : HI;L; 3.85 (q) : H2; 4.27: H and H5; 4.63<br>
(m): CH2-N; 4.99 (dd): H13; 5.46 (t): NH-CH2; 7.10-7.64-7.66-<br>
7.97: aromatics.<br>
EXAMPLE IS; 11,12-dideoxy 3-de ((2,6-dideoxy 3-C-methyl 3-O-<br>
methyl alpha-L-ribohexopyranosyl) oxy) 6-O-methyl 3-oxo<br>
12,ll-(oxycarbonyl 2-(3-(3H-imidazo (4,5-b)pyridin-3-yl)<br>
propyl) hydrazono)) erythromycin.<br>
NMR (CDC13) 300 MHz:<br>
0.85 (t): CH3-CH2; 1.09-1.19 (d)-1.25 (d)-1.31 (d)-1.34 (d):<br>
the CH3CH's; 1.33 and 1.48: 6 and 12 Me; 1.57 and 1.96: CH2<br>
in position 14;<br>
1.66 and 1.87: CH2 in position 7; 2.05 and 2.18: CH2-CH2-CH2;<br>
2.26 (s): N(CH3)2; 2.44 (ro) : H'3; 2.6 (s): 6-OCH3; 2.66 (m):<br>
H8; 2.70 to 2.85: CH2NH; 3.04 (m): H4; 3.18: H2, HIQ; 3.70<br>
(s) : H1]L; 3.85 (q) : H2; 4.27: H'  and H5; 4.42 to 4.70: CH-.-<br>
N; 4.97 (dd): H13; 5.56 (t): NH; 8.22 (dd)-8.05 (d)-8.28 (s)-<br>
8.38 (d): aromatics.<br>
EXAMPLE 16; 11,12-dideoxy 3-de ((2,6-dideoxy 3-C-methyl 3-O-<br>
methyl alpha-L-ribohexopyranosyl) oxy 6-O-methyl 3-oxo 12,11-<br>
(oxycarbonyl 2-(3-(l/l'-biphenyl-4-yl) propyl) hydrazono))<br>
crythromycin.<br>
NMR (CDC13) 300 MHz:<br>
0.87 (t): CH3-CH2; 1.08 (d)-1.18 (d)-1.23 (d)-1.32 (d)-1.38<br>
(d): the CH3~CH's; 1.34 (s) and 1.48 (s): 6 and 12 Me; 2.26<br>
(s): N(CH3)2; 2.44 (m): H73; 2.65 (s): 6-OCH3; 2.65 (m) Hg;<br>
2.77 (m) CH2-Ar; 2.85 (t): CH2NH; 3.07 (m): H4; 3.18 (m) :<br>
H'2/ H10; 3.25 (m) : H75; 3.76 (s) : HI;L; 3.87 (q) : H2; 4.27:<br>
H'± and H5; 5.04 (dd): H13; 5.37 (t): NH-CH2; 7.25 to 7.6:<br>
aromatics.<br>
EXAMPLE 17; 11,12-dideoxy 3-de ((2,6-dideoxy 3-C-methyl 3-D-<br>
methyl alpha-L-ribohexopyranosyl) oxy) 6-O-methyl 3-oxo<br>
12,ll-(oxycarbonyl 2-(3-(2-phenyl 4-thiazolyl) propyl)<br>
hydrazono)) erythromycin.<br>
NMR (CDC13) 300 MHz:<br>
0.86 (t) : CH3-CH2; 1.07 (d)-1.19 (d)-1.24 (d)-1.31 (d)-1.35<br>
(d) : the CH3-CH; 1.32 (s)-1.48 (s) : 6-CH3 and 12-CH3; 2.26<br>
(s): N(CH3)2; 2.65 (s) : 6-OCH3 : 2.45 (m) : H'3; 2.65 (m) : H8;<br>
2.8 to 3.25 (m) : H4 , HIQ/ H'2/ CH2-Ar and CH2N; 3.53 (m) :<br>
H'5; 3.76 (m) : Hllf- 3.86 (q) : H2 ; 4.27 (d) : H and H5; 5.04<br>
(dd) : H13; 5.36 (t) : NH; 6.96-7.40-7.93: aromatics.<br>
EXAMPLE 18: 11,12-dideoxy 3-de ( (2, 6-dideoxy 3-C-methyl 3-O-<br>
methyl alpha-L-ribohexopyranosyl) oxy) 6-O-methyl 3-oxo<br>
12,ll-(oxyoarbonyl 2-(3-(5-phenyl l/2/4-thiadiazol-3-yl)<br>
propyl) hydra zono) ) erythromycin.<br>
NMR (CDC13) 300 MHz:<br>
0.87 (t) : CH3-CH2; 1.33 and 1.47: 6 and 12 Me; 2.17 (m) : CH2-<br>
CH2-CH2; 2.26 (S) : N(CH3)2; 2.67 (s) : 6-OCH3 ; 2.67 (s) : Hg ;<br>
3.76 (s) : H1;L; 3.85 (q) : H2 ; 5.06 (dd) : H13; 5.39 (t) : Nfl-<br>
CH2; 7.49-7.94: aromatics.<br>
EXAMPLE 19; 11,12-dideoxy 3-de ( (2, 6-dideoxy 3-C-methyl 3-O-<br>
methyl alpha-L-ribohexopyranosyl) oxy) 6-O-methyl 3-oxo<br>
I2,ll-(oxycarbonyl 2- (3-(4-(4-chlorophenyl-lH-imidazol-l-yl)<br>
propyl) hydrazono) ) erythromycin.<br>
By operating as previously, the compounds of formula (I) were prepared in which the radical<br>
N         represents the radical<br>
(Figure Removed) <br>
EXAMPLE OF PHARMACEUTICAL COMPOSITION<br>
Tablets were prepared containing:<br>
Product of Example 5 	 150 nig<br>
Excipient s.q.f	   Ig<br>
Detail of the excipient: starch, talc, magnesium stearate PHARMACOLOGICAL STUDY OF THE PRODUCTS OF THE INVENTION Method of dilutions in liquid media<br>
A series of tubes was prepared into which an equal quantity of sterile nutritive medium is distributed. Increasing quantities of the product being studied is distributed into each tube, then each tube is seeded with a bacterial strain.<br>
After incubation for twenty-four hours in a heating chamber at 37°C, the growth inhibition is evaluated by trans-illumination, which allows the minimal inhibiting<br><br>
concentrations (M.I.C.) to be determined, expressed in micrograms/cm3.<br>
The following results were obtained with the product of Example 5: (reading after 24 hours)<br>
GRAM+ bacterial strains<br>
Staphylococcus aureus 011UC4	0.02<br>
Staphylococcus aureus 011G025I	0.08<br>
Staphylococcus epidermidis 012GO11I         0.04<br>
Streptococcus pyogenes	
group A 02A1UC1<br>
Streptococcus agalactiae	
group B 02B1HT1<br>
Streptococcus faecalis	
group D 02D2UC1<br>
Streptococcus faecium	
group D 02D3HT1<br>
Streptococcus sp	
group G 02GOGR5<br>
Streptococcus mitis	
02mitCBl<br>
Streptococcus agalactiae	
group B 02B1SJ1<br>
Streptococcus pneumoniae	
032UC1<br>
Streptococcus pneumoniae	
030SJ5<br>
Moreover, the product of Example 5 demonstrated a useful activity on the GRAM" bacterial strains Haemophilus Influenzae 351HT3, 351CB12, 351CA1 and 351GR6.<br>
The compounds of examples 12 and 13 have equally demonstrated an excellent activity on the gram (-) and gram (+) bacterial strains.<br>
In this way, operating as indicated previously, the following results were obtained with the compounds of examples 12 and 13 (reading after 24 hours).<br><br>
GRAM+ bacterial strains	Ex.12    Ex.13<br>
Staphylococcus aureus	0,08     0,04<br>
011UC4<br>
Staphylococcus aureus	0,08     0,15<br>
011G025I Staphylococcus epidermidis         0,04     0,04<br>
012G011I<br>
Streptococcus pyogenes	
02A1UC1 Streptococcus agalactiae         
02B1HT1<br>
Streptococcus faecalis	
02D2UC1<br>
Streptococcus faecium	
02D3HT1<br>
Streptococcus pneumoniae	0,04   
032UC1<br>
Streptococcus pneumoniae	
030SJ5I<br>
Streptococcus pneumoniae	0,6      0,6<br>
030CR18C<br>
Haemophilus inflienzae	1,2      0,6<br>
351HT3<br>
Haemophilus inflienzae	1,2      1,2<br>
351CB12<br><br><br><br><br><br>
WE CLAIM:<br>
1. The compounds of general formula (I):<br><br>
(Formula Removed) <br><br>
in which:<br>
either R1 and R2, identical or different, represent a<br>
hydrogen atom, or a hydrocarbon radical containing up to 24<br>
carbon atoms, saturated or unsaturated, optionally<br>
interrupted by one or more heteroatoms and optionally<br>
carrying one or more functional groups,<br>
or R1 and R2, form with the nitrogen atom to which they are<br>
linked a heterocycle optionally containing one or more<br>
heteroatoms chosen from nitrogen, oxygen and sulphur,<br>
or R1 and R2,<br>
together form a radical<br>
(Formula Removed) <br><br><br>
in which R1 and R2,identical or different, represent a hydrogen atom or a hydrocarbon radical containing up to 23 carbon atoms, saturated or unsaturated, optionally interrupted by one or more heteroatoms and optionally carrying one or more functional groups and Z represents a hydrogen atom or the remainder of a carboxylic acid containing up to 18 carbon atoms, the wavy line in position 10 indicating that the methyl can be of R or S configuration or a mixture of R + S, as well as the addition salts with<br><br>
acids of the compounds of Formula (I).<br>
2.	The compounds of Formula (I) as claimed in claim 1 wherein Z represents a<br>
hydrogen atom.<br>
3.	The   compounds  of Formula   (I)   as  claimed  in   claims   1   or  2  wherein<br>
R1represents a hydrogen atom.<br>
4.	The compounds of Formula (I) as claimed in claims 1 or 2 wherein R1 and R2<br>
each represents a hydrogen atom.<br>
5.	The  compounds  of Formula  (I)   as  claimed  in  claims   1   or  2  wherein<br>
R'irepresents a hydrogen atom.<br>
6.	The compounds of Formula (I) as claimed in claims 1, 2 or 5 wherein Riand<br>
R2 together form the radical:<br>
(Formula Removed) <br>
in which Ar1   represents  an  optionally substituted aryl  or heteroaryl radical and n represents  an  integer  which can vary from 0 to 8.<br>
7.	The compounds of Formula (I) as claimed in claims 1, 2 or 5 wherein Riand<br>
R2 together form the radical:<br>
(Formula Removed)<br>
in which p and q,   identical or different,   represent an integer varying from  0 to  6,   A and B,   identical  or different, represent a hydrogen or halogen atom or an alkyl radical containing up to 8  carbon atoms,   the geometry of the double bond being E or Z or an E + Z mixture,<br>
or A and B  form a third bond with the carbon atoms to which they are  linked and Ar2 represents an optionally substituted mono- or polycyclic aryl or heteroaryl radical.<br>
8.	The compounds of Formula (I) as claimed in claims 1 or 2, wherein p and q represent the number 0.<br>
9.	The compounds of Formula (I) as claimed in claim 7 or 8 wherein A and B represents a hydrogen atom.<br>
10.	The compounds of Formula (I) as claimed in claims 1, 2 or 3 wherein R2<br>
represents the radical:<br>
(Formula Removed) <br>
in which r represents an integer varying from o to 6 and Ar3 represents an optionally substituted aryl or heteroaryl 5 radical.11)   The compounds of formula (I) as defined in claim 10, in which Ar3 represents a 4-quinolinyl radical optionally mono— or polysubatifcufced on one and/or the other of the 2 rings of the quinoline.<br>
11.	The compounds of formula (I) as claimed in claim 10, wherein Ar3 represents a 4-quinolinyl radical optionally mono- or poly- substituted on one and/or the other of the 2 rings of the quinoline.<br>
12.	The compounds of formula (I) as claimed in claim 10, wherein Ar3 represents a non- substituted 4-quinolinyl radical.<br>
13.	The compounds of formula (I) as claimed in claim 10, wherein Are represents a 4-quinolinyl radical substituted with a methoxy radical.<br>
14.	The compounds of formula (I) as claimed in claim 10, wherein Are represents a thiazolyl radical, substituted by a pyridyl radical.<br><br>
15.	The compounds of formula (I) as claimed in any one of the claims 10 to 14, wherein r represents an integer carrying from 1 to 4.<br>
16.	The compounds of Formula (I) as claimed in claim 1, wherein it is selected from the group consisting of:<br><br>
-	11,12-dideoxy   3-de((2,6-dideoxy  3-c-methyl   3-O-methyl   alph L-ribohexopyranosyI)    oxy)    6-O-methyl   3-oxo   12,11-(oxycarbonyl   (2-(3-(4-quinolinyl)   2-propyl)   hydrazono)} erythromycin,<br>
-	11,12-dideoxy  3-de   ((2,6-dideoxy  3-C-methyl   3-O-methyl alpha-L-ribohexopyianosyl)   oxy)    6-O-methyl  3-oxo   12,ll-(oxy-carbonyl   {2-(3-(4-quinoleinyl)   propyl)   hydrazono))    erythromy cine,<br>
-	11,12-dideoxy   3-de   ((2,6-dideoxy   3-c-methyl   3-O-methyl alpha-L-ribohexopyranosyl)    oxy)    6-O-roethyl   3-oxo   12,ll-(oxy-carbonyl   (2-(3-(7-methoxy-4-quinoleinyl)   propyl)    hydrazono)) erythromycine,<br>
-	11,12-dideoxy   3-de    ((2,6-dideoxy   3-C-methyl   3-O-methyl alpha-L-ribohexopyranosyl)    oxy)   6-O-methyl   3-oxo   l2,ll-(oxy-<br>
.  carbonyl   (2-(3-(2-(3-pyridinyl-4-thiazolyl)   propyl)   hydrazono))   erythz omycine.<br><br>
17. A compound as claimed in any one of the preceding claims as medicament.<br>
18. The pharmaceutical compositions containing as active ingredient at least one compounds of formula (I) as defined in any one of claims 1 to 16. claim 17<br>
19. Preparation process for the compounds of formula (I) as claimed in claim 1, wherein a compound of formula (II):<br><br>
(Formula Removed) <br>
in which Z retains the meaning indicated in claim 1,   is<br>
subjected<br>
either to the action of hydrazine NH2NH2 in order to obtain<br>
the compound of formula (IA) :<br>
(Formula Removed) <br><br>
which is subjected if desired to the action of an R'2CHO<br><br>
aldehyde or of a cetone R'1-OR'2 in which R'1 and R'2 retain the meaning indicated in claim 1 in order to obtain the<br>
corresponding compound of formula (IB):<br><br>
(Formula Removed)<br>
in which R1 and R2,retain the same meaning as previously, which is subjected if desired to the action of a reducing agent in order to obtain the corresponding compound of formula (Ic):<br>
(Formula Removed) <br><br>
in which R'1 and R'2 retain the previous meaning, that is a compound of formula (I) in which R1 represents hydrogen atom and R2 represents a CHR1R'2 radical, then if desired, the compound of formula (Ic) is subjected to the action of an agent capable of replacing the hydrogen atom of the NH group by an R2 group as defined in claim 1 with the exception of the hydrogen value, then if desired, the compounds obtained are subjected to the action of an acid in order to form the salt and/or to the action of an esterification agent of the OH group in position 2'.<br>
20. Process for the preparation of the compounds of Formula (I) as claimed in claim 1 substantially as herein described with reference to the foregoing examples.<br><br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1ERUwtMTk5NS1BYnN0cmFjdC0oMjYtMDYtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1168-DEL-1995-Abstract-(26-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">1168-del-1995-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1ERUwtMTk5NS1DbGFpbXMtKDIwLTAyLTIwMDkpLnBkZg==" target="_blank" style="word-wrap:break-word;">1168-DEL-1995-Claims-(20-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1ERUwtMTk5NS1DbGFpbXMtKDI2LTA2LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1168-DEL-1995-Claims-(26-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">1168-del-1995-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1ERUwtMTk5NS1Db3JyZXNwb25kZW5jZS1PdGhlcnMtKDIwLTAyLTIwMDkpLnBkZg==" target="_blank" style="word-wrap:break-word;">1168-DEL-1995-Correspondence-Others-(20-02-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1ERUwtMTk5NS1Db3JyZXNwb25kZW5jZS1PdGhlcnMtKDI2LTA2LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1168-DEL-1995-Correspondence-Others-(26-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1jb3JyZXNwb25kZW5jZS1vdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">1168-del-1995-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1kZXNjcmlwdGlvbiAoY29tcGxldGUpLTI2LTA2LTIwMDgucGRm" target="_blank" style="word-wrap:break-word;">1168-del-1995-description (complete)-26-06-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1kZXNjcmlwdGlvbiAoY29tcGxldGUpLnBkZg==" target="_blank" style="word-wrap:break-word;">1168-del-1995-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1ERUwtMTk5NS1Gb3JtLTEtKDI2LTA2LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1168-DEL-1995-Form-1-(26-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1mb3JtLTEucGRm" target="_blank" style="word-wrap:break-word;">1168-del-1995-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1mb3JtLTEwLnBkZg==" target="_blank" style="word-wrap:break-word;">1168-del-1995-form-10.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1mb3JtLTE4LnBkZg==" target="_blank" style="word-wrap:break-word;">1168-del-1995-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1ERUwtMTk5NS1Gb3JtLTItKDI2LTA2LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1168-DEL-1995-Form-2-(26-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1mb3JtLTIucGRm" target="_blank" style="word-wrap:break-word;">1168-del-1995-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1ERUwtMTk5NS1Gb3JtLTMtKDI2LTA2LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1168-DEL-1995-Form-3-(26-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1mb3JtLTQucGRm" target="_blank" style="word-wrap:break-word;">1168-del-1995-form-4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1mb3JtLTYucGRm" target="_blank" style="word-wrap:break-word;">1168-del-1995-form-6.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1ERUwtMTk5NS1HUEEtKDI2LTA2LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1168-DEL-1995-GPA-(26-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1ncGEucGRm" target="_blank" style="word-wrap:break-word;">1168-del-1995-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1ERUwtMTk5NS1QZXRpdGlvbi0xMzctKDI2LTA2LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1168-DEL-1995-Petition-137-(26-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1ERUwtMTk5NS1QZXRpdGlvbi0xMzgtKDI2LTA2LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1168-DEL-1995-Petition-138-(26-06-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTE2OC1kZWwtMTk5NS1wZXRpdGlvbi0xMzgucGRm" target="_blank" style="word-wrap:break-word;">1168-del-1995-petition-138.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QuanBn" target="_blank" style="word-wrap:break-word;">abstract.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="233260-lyophilized-composition-of-kahalalide-f.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="233262-water-soluble-anionic-tetracyclic-7-8-17-18-tetrahydroporphyrin-compounds-and-preparation-thereof.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>233261</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1168/DEL/1995</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>13/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>27-Mar-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>27-Mar-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>23-Jun-1995</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>AVENTIS PHARMA S.A.,</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>20 AVENUE RAYMOND-IRON, F-92160 ANTONY, FRANCE.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>ODILE LE MARTRET</td>
											<td>42, AVENUE DE VERSAILLES, F-75016 PARIS, FRANCE.</td>
										</tr>
										<tr>
											<td>2</td>
											<td>CONSTANTIN AGOURIDAS</td>
											<td>107, BOULEVARD DE STRASBOURG, F-94130 NOGENT SUR MARNE, FRANCE.</td>
										</tr>
										<tr>
											<td>3</td>
											<td>YANNICK BENEDETTI</td>
											<td>2, ALLEE DE LA 2EME DB, F-93110 ROSNY SOUS BOIS, FRANCE.</td>
										</tr>
										<tr>
											<td>4</td>
											<td>JEAN-FRANCOIS CHANTOT</td>
											<td>7, RUE PASTEUR, F-94130 NOGENT SUR MARNE, FRANCE.</td>
										</tr>
										<tr>
											<td>5</td>
											<td>ALEXIS DENIS</td>
											<td>37, RUE GODEFROY CAVAIGNAS, F-75011 PARIS, FRANCE.</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>95 03334</td>
									<td>1995-03-22</td>
								    <td>France</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/233261-14-membered-lactone-ring-compounds-their-preparation-process-and-use-as-medicaments by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:36:42 GMT -->
</html>
